Fate Therapeutics Inc ( (FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fate Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. In its latest earnings report, Fate Therapeutics highlighted a restructuring initiative aimed at streamlining operations and extending its cash runway, alongside ongoing collaborations to advance its product pipeline. The company reported a net loss of $32.25 million for the third quarter of 2025, compared to a $47.68 million loss in the same period last year, with collaboration revenue decreasing to $1.74 million from $3.07 million. Despite the financial losses, Fate Therapeutics continues to invest in research and development, with expenses totaling $25.84 million for the quarter. The company remains focused on its strategic partnerships, particularly with Ono Pharmaceutical Co., Ltd., which has been a significant contributor to its collaboration revenue. Looking ahead, Fate Therapeutics aims to leverage its iPSC platform and strategic collaborations to advance its clinical programs and achieve key milestones in the coming years.